Risks associated with Sirolimus and COVID-19
Sirolimus is efficient for immunosuppression in transplant patients where it acts prophylactically especially in renal transplant. It increases susceptibility to infection due to which patients are at high risk for COVID-19. It can cause complications like lowering of lung function like FEV1 (forced expiratory volume). It is important to follow CDC guidelines as recommended. Moreover, it is also advised that LAM (lymphangioleiomyomatosis) patients who suffer from abnormal growth of muscle like cells in lungs, lymph nodes or kidneys are at high risk of contracting COVID-19 due to intake of Sirolimus. But, due to the nature of their illness, it is advisable that they continue with their treatment plan. It is important for the healthcare provider to decide upon dose reduction or treatment interruption in certain circumstances wherein patients are at high risk of COVID-19 transmission [22].